odalasvir + simeprevir + ritonavir + ribavirin

This drug is a **combination therapy** of four antiviral agents: odalasvir, simeprevir, ritonavir, and ribavirin. It is being researched for the treatment of chronic hepatitis C virus (HCV) infection. - **Odalasvir** is an NS5A inhibitor, blocking viral RNA replication. - **Simeprevir** is an NS3/4A protease inhibitor, preventing viral protein processing. - **Ritonavir** is used as a pharmacokinetic booster, increasing the levels of simeprevir by inhibiting CYP3A-mediated metabolism. - **Ribavirin** is a nucleoside analog with antiviral effects, commonly used in HCV regimens. The combination targets multiple steps of the HCV replication cycle, and is tested primarily in direct-acting antiviral (DAA) regimens. These combinations have been evaluated in **Phase 2 clinical trials for HCV genotype 1 infection**, often with the aim of improving sustained virological response rates after treatment.